Feasibility and clinical impact of rapid respiratory virus testing in a real-world setting
Not Applicable
Completed
- Conditions
- Influenza and respiratory syncytial virusInfections and InfestationsInfluenza, virus not identified
- Registration Number
- ISRCTN10110119
- Lead Sponsor
- niversity of Calgary
- Brief Summary
2022 Preprint results in https://doi.org/10.21203/rs.3.rs-1618007/v1 (added 18/07/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36384484/ (added 18/11/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 1090
Inclusion Criteria
All patients with a respiratory virus nucleic acid test ordered by a physician at one of the two study hospitals
Exclusion Criteria
Patients without a respiratory virus nucleic acid test ordered by a physician at one of the two study hospitals
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Turnaround time for the rapid NAT or standard of care test, as measured from the time of collection of the sample to the verification of the result. Time of collection submitted by the collector and recorded in the laboratory information system (LIS). Time of result is when reported by the laboratory in the LIS. Times will be retrieved from the LIS at the end of the study.<br> 2. Pediatric site (site 1) - Duration of hospital stay for patients tested for respiratory viruses, defined as the time from ER admission to hospital discharge or hospital admission to hospital discharge if ER admission time is not available. Patients seen only in ER will not be included in this endpoint. This is recorded in the clinical information system (CIS) and will be retrieved from there.<br> 3. Adult/pediatric site (site 2) – a prescription of oseltamivir recorded in the CIS during the encounter. Data will be retrieved from the CIS.<br>
- Secondary Outcome Measures
Name Time Method